116 related articles for article (PubMed ID: 15731318)
1. New tools for optimizing endometrial receptivity in controlled ovarian hyperstimulation: aromatase inhibitors and LH/(mini)hCG.
de Ziegler D; Mattenberger C; Schwarz C; Ibecheole V; Fournet N; Bianchi-Demicheli F
Ann N Y Acad Sci; 2004 Dec; 1034():262-77. PubMed ID: 15731318
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors in ovulation induction.
Mitwally MF; Casper RF
Semin Reprod Med; 2004 Feb; 22(1):61-78. PubMed ID: 15083382
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
Filicori M; Cognigni GE; Gamberini E; Parmegiani L; Troilo E; Roset B
Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
[TBL] [Abstract][Full Text] [Related]
4. Recombinant gonadotropins.
Lathi RB; Milki AA
Curr Womens Health Rep; 2001 Oct; 1(2):157-63. PubMed ID: 12112963
[TBL] [Abstract][Full Text] [Related]
5. Ovulation induction: a mini review.
Messinis IE
Hum Reprod; 2005 Oct; 20(10):2688-97. PubMed ID: 16006478
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial.
Barroso G; Menocal G; Felix H; Rojas-Ruiz JC; Arslan M; Oehninger S
Fertil Steril; 2006 Nov; 86(5):1428-31. PubMed ID: 16978619
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
8. [Controlled ovarian hyperstimulation (COH) and management of low-responder cases (HOO)].
Vladimirov IaK
Akush Ginekol (Sofiia); 2003; 42(3):23-6. PubMed ID: 12858487
[TBL] [Abstract][Full Text] [Related]
9. GnRH antagonists in ovarian stimulation for IVF.
Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
[TBL] [Abstract][Full Text] [Related]
11. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
12. Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome.
Bosch E; Escudero E; Crespo J; Simón C; Remohí J; Pellicer A
Fertil Steril; 2005 Nov; 84(5):1529-32. PubMed ID: 16275263
[TBL] [Abstract][Full Text] [Related]
13. The future trends of induction of ovulation.
Check JH
Minerva Endocrinol; 2010 Dec; 35(4):227-46. PubMed ID: 21178918
[TBL] [Abstract][Full Text] [Related]
14. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
15. Letrozole co-treatment in infertile women 40 years old and older receiving controlled ovarian stimulation and intrauterine insemination.
Bedaiwy MA; Shokry M; Mousa N; Claessens A; Esfandiari N; Gotleib L; Casper R
Fertil Steril; 2009 Jun; 91(6):2501-7. PubMed ID: 18501899
[TBL] [Abstract][Full Text] [Related]
16. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
[TBL] [Abstract][Full Text] [Related]
17. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
[TBL] [Abstract][Full Text] [Related]
18. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?
Orvieto R; Meltzer S; Rabinson J; Gemer O; Anteby EY; Nahum R
Fertil Steril; 2008 Oct; 90(4):1297-300. PubMed ID: 18249369
[TBL] [Abstract][Full Text] [Related]
19. Developments in drugs for ovarian stimulation.
Ludwig M; Westergaard LG; Diedrich K; Andersen CY
Best Pract Res Clin Obstet Gynaecol; 2003 Apr; 17(2):231-47. PubMed ID: 12758097
[TBL] [Abstract][Full Text] [Related]
20. A new era in ovulation induction.
Holzer H; Casper R; Tulandi T
Fertil Steril; 2006 Feb; 85(2):277-84. PubMed ID: 16595197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
